VX2

You have access
Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro
NORBERT NASS, SEBASTIAN STREIT, CHRISTIAN WYBRANSKI, JULIAN JÜRGENS, JAN BRAUNER, NADINE SCHULZ, MACIEJ POWERSKI, JENS RICKE, THOMAS KALINSKI, OLIVER DUDECK and MAX SEIDENSTICKER

Anticancer Research January 2017, 37 (1) 87-93;
You have access
bFGF Up-regulation Reduces Spontaneous Necrosis of VX2 Tumors Without Increasing Tumoral Microvascular Density
FLORENTINA PASCALE, SAIDA-HOMAYRA GHEGEDIBAN, LAURENT BEDOUET, JULIEN NAMUR, MICHEL BONNEAU, VALENTIN VERRET, ISABELLE SCHWARTZ-CORNIL, MICHEL WASSEF and ALEX LAURENT

Anticancer Research July 2016, 36 (7) 3315-3320;
You have access
Comparative Chemosensitivity of VX2 and HCC Cell Lines to Drugs Used in TACE
FLORENTINA PASCALE, LAURENT BEDOUET, MINTHAM BAYLATRY, JULIEN NAMUR and ALEXANDRE LAURENT

Anticancer Research December 2015, 35 (12) 6497-6503;

Main menu